Top

Published in:

01-06-2009 | Short Communication

Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia

Authors: Tohid Kazemi, Hossein Asgarian-Omran, Ali Memarian, Mahdi Shabani, Ramazan A. Sharifian, Parvaneh Vossough, Bita Ansaripour, Hodjatallah Rabbani, Fazel Shokri

Published in: Cancer Immunology, Immunotherapy | Issue 6/2009

Abstract

Recent studies have demonstrated expression of Fc receptor-like (FCRL) molecules, a newly identified family with preferential B-cell lineage expression, in some chronic B-cell leukemias with possible implication for classification and/or targeted immunotherapy. In this study, the expression pattern of FCRL1-5 genes was studied in 73 Iranian ALL patients and 35 normal subjects using semi-quantitative RT-PCR method. FCRL protein expression was also investigated by flow cytometry. Our results indicate significant down-regulation of all FCRL genes in ALL compared to normal subjects. Although, FCRL mRNA expression was almost exclusively confined to normal isolated B-cells compared to T-cells, but these genes were similarly expressed in B-ALL, T-ALL and different B-ALL immunophenotypic subtypes. Surface protein expression of FCRL1, 2, 4, and 5 molecules in 10 ALL and 5 normal samples confirmed the PCR results. Expression profile of FCRL molecules in different subtypes of ALL argues against their potential implication as suitable targets for classification and/or immunotherapy of ALL.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511PubMedCrossRef

Asgarian Omran H, Shabani M, Shahrestani T, Sarafnejad A, Khoshnoodi J, Vossough P, Faranoush M, Sharifian RA, Jeddi-Tehrani M, Rabbani H, Shokri F (2007) Immunophenotypic subtyping of leukemic cells from Iranian patients with acute lymphoblastic leukaemia: association to disease outcome. Iran J Immunol 4(1):15–25PubMed

Busson P, McCoy R, Sadler R, Gilligan K, Tursz T, Raab-Traub N (1992) Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J Virol 66(5):3257–3262PubMed

Davis RS (2007) Fc receptor-like molecules. Annu Rev Immunol 25:525–560PubMedCrossRef

Davis RS, Dennis G Jr, Odom MR, Gibson AW, Kimberly RP, Burrows PD, Cooper MD (2002) Fc receptor homologs: newest members of a remarkably diverse Fc receptor gene family. Immunol Rev 190:123–136PubMedCrossRef

Davis RS, Ehrhardt GR, Leu CM, Hirano M, Cooper MD (2005) An extended family of Fc receptor relatives. Eur J Immunol 35(3):674–680PubMedCrossRef

Davis RS, Wang YH, Kubagawa H, Cooper MD (2001) Identification of a family of Fc receptor homologs with preferential B cell expression. Proc Natl Acad Sci USA 98(17):9772–9777PubMedCrossRef

Du X, Nagata S, Ise T, Stetler-Stevenson M, Pastan I (2008) FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 111(1):338–343PubMedCrossRef

Ehrhardt GR, Davis RS, Hsu JT, Leu CM, Ehrhardt A, Cooper MD (2003) The inhibitory potential of Fc receptor homolog 4 on memory B cells. Proc Natl Acad Sci USA 100(23):13489–13494PubMedCrossRef

10.

Ehrhardt GR, Hsu JT, Gartland L, Leu CM, Zhang S, Davis RS, Cooper MD (2005) Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med 202(6):783–791PubMedCrossRef

11.

Foa R, Vitale A (2002) Towards an integrated classification of adult acute lymphoblastic leukemia. Rev Clin Exp Hematol 6 (2): 181–99 (discussion 200-2)

12.

Gokbuget N, Hoelzer D (2002) Recent approaches in acute lymphoblastic leukemia in adults. Rev Clin Exp Hematol 6(2):114–141 (discussion 200-2)PubMedCrossRef

13.

Haga CL, Ehrhardt GR, Boohaker RJ, Davis RS, Cooper MD (2007) Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment. Proc Natl Acad Sci USA 104(23):9770–9775PubMedCrossRef

14.

Han X, Bueso-Ramos CE (2005) Advances in the pathological diagnosis and biology of acute lymphoblastic leukemia. Ann Diagn Pathol 9(4):239–257PubMedCrossRef

15.

Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S, Tagawa S, Taniwaki M, Russo J, Neri A, Cattoretti G, Clynes R, Mendelsohn C, Chaganti RS, Dalla-Favera R (2001) IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 14(3):277–289PubMedCrossRef

16.

Ise T, Maeda H, Santora K, Xiang L, Kreitman RJ, Pastan I, Nagata S (2005) Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies. Clin Cancer Res 11(1):87–96PubMed

17.

Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M, Bishop MR, Scheinberg DA, Rassenti L, Kipps TJ, Kyle RA, Jelinek DF, Pastan I (2007) Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 21(1):169–174PubMedCrossRef

18.

Itoyama T, Nanjungud G, Chen W, Dyomin VG, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD, Chaganti RS (2002) Molecular cytogenetic analysis of genomic instability at the 1q12–22 chromosomal site in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer 35(4):318–328PubMedCrossRef

19.

Jabbour EJ, Faderl S, Kantarjian HM (2005) Adult acute lymphoblastic leukemia. Mayo Clin Proc 80(11):1517–1527PubMedCrossRef

20.

Kohlmann A, Schoch C, Schnittger S, Dugas M, Hiddemann W, Kern W, Haferlach T (2004) Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients. Leukemia 18(1):63–71PubMedCrossRef

21.

Kuchinskaya E, Heyman M, Grander D, Linderholm M, Soderhall S, Zaritskey A, Nordgren A, Porwit-Macdonald A, Zueva E, Pawitan Y, Corcoran M, Nordenskjold M, Blennow E (2005) Children and adults with acute lymphoblastic leukaemia have similar gene expression profiles. Eur J Haematol 74(6):466–480PubMedCrossRef

22.

Leu CM, Davis RS, Gartland LA, Fine WD, Cooper MD (2005) FcRH1: an activation coreceptor on human B cells. Blood 105(3):1121–1126PubMedCrossRef

23.

Li FJ, Ding S, Pan J, Shakhmatov MA, Kashentseva E, Wu J, Li Y, Soong SJ, Chiorazzi N, Davis RS (2008) FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. Blood 112(1):179–187PubMedCrossRef

24.

Maltais LJ, Lovering RC, Taranin AV, Colonna M, Ravetch JV, Dalla-Favera R, Burrows PD, Cooper MD, Davis RS (2006) New nomenclature for Fc receptor-like molecules. Nat Immunol 7(5):431–432PubMedCrossRef

25.

Mikaelsson E, Danesh-Manesh AH, Luppert A, Jeddi-Tehrani M, Rezvany MR, Sharifian RA, Safaie R, Roohi A, Osterborg A, Shokri F, Mellstedt H, Rabbani H (2005) Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Blood 105(12):4828–4835PubMedCrossRef

26.

Nakayama Y, Weissman SM, Bothwell AL (2001) BXMAS1 identifies a cluster of homologous genes differentially expressed in B cells. Biochem Biophys Res Commun 285(3):830–837PubMedCrossRef

27.

Offit K, Wong G, Filippa DA, Tao Y, Chaganti RS (1991) Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin’s lymphoma: clinical correlations. Blood 77(7):1508–1515PubMed

28.

Omran HA, Shabani M, Vossough P, Sharifian R, Tabrizi M, Khoshnoodi J, Jeddi-Tehrani M, Rabbani H, Shokri F (2008) Cross-sectional monitoring of Wilms’ tumor gene 1 (WT1) expression in Iranian patients with acute lymphoblastic leukemia at diagnosis, relapse and remission. Leuk Lymphoma 49(2):281–290PubMedCrossRef

29.

Polson AG, Zheng B, Elkins K, Chang W, Du C, Dowd P, Yen L, Tan C, Hongo JA, Koeppen H, Ebens A (2006) Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol 18(9):1363–1373PubMedCrossRef

30.

Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M, Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H, Delabie J, Staudt LM (2003) The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3(2):185–197PubMedCrossRef

31.

Shabani M, Asgarian Omran H, Jeddi-Tehrani M, Vossough P, Faranoush M, Sharifian RA, Toughe GR, Kordmahin M, Khoshnoodi J, Roohi A, Tavoosi N, Mellstedt H, Rabbani H, Shokri F (2008) Overexpression of Orphan Receptor Tyrosine Kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol 28(6):318–326CrossRef

32.

Won WJ, Foote JB, Odom MR, Pan J, Kearney JF, Davis RS (2006) Fc receptor homolog 3 is a novel immunoregulatory marker of marginal zone and B1 B cells. J Immunol 177(10):6815–6823PubMed

Title: Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia
Authors: Tohid Kazemi
Hossein Asgarian-Omran
Ali Memarian
Mahdi Shabani
Ramazan A. Sharifian
Parvaneh Vossough
Bita Ansaripour
Hodjatallah Rabbani
Fazel Shokri
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 6/2009
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-008-0589-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2

HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody

Focal adhesion kinase as an immunotherapeutic target

Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy

Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients

Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer